Brainstorm Cell Therapeutics Files 8-K on Financials
Ticker: BCLI · Form: 8-K · Filed: Aug 14, 2024 · CIK: 1137883
| Field | Detail |
|---|---|
| Company | Brainstorm Cell Therapeutics Inc. (BCLI) |
| Form Type | 8-K |
| Filed Date | Aug 14, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00005 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
TL;DR
Brainstorm Cell Therapeutics dropped an 8-K on August 14th detailing their financial condition and results. Check it for the latest numbers.
AI Summary
On August 14, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing pertains to the company's results of operations and financial condition, as well as financial statements and exhibits. The report was filed as of August 14, 2024.
Why It Matters
This filing provides crucial updates on Brainstorm Cell Therapeutics' financial health and operational results, which are essential for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing reporting on financial condition and results, not indicating any immediate or significant new risks.
Key Players & Entities
- Brainstorm Cell Therapeutics Inc. (company) — Registrant
- August 14, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Brainstorm Cell Therapeutics Inc.'s results of operations and financial condition, along with financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 14, 2024.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
What is the company's IRS Employer Identification Number?
The company's IRS Employer Identification Number is 20-7273918.
What is the Standard Industrial Classification code for Brainstorm Cell Therapeutics Inc.?
The Standard Industrial Classification code for Brainstorm Cell Therapeutics Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-08-14 07:15:21
Key Financial Figures
- $0.00005 — nge on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market L
Filing Documents
- tm2421455d1_8k.htm (8-K) — 24KB
- tm2421455d1_ex99-1.htm (EX-99.1) — 87KB
- 0001104659-24-089295.txt ( ) — 292KB
- bcli-20240814.xsd (EX-101.SCH) — 3KB
- bcli-20240814_lab.xml (EX-101.LAB) — 33KB
- bcli-20240814_pre.xml (EX-101.PRE) — 22KB
- tm2421455d1_8k_htm.xml (XML) — 4KB
02. Results of Operations and Financial
Item 2.02. Results of Operations and Financial Condition. On August 14, 2024, Brainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the quarter ended June 30, 2024. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release issued by Brainstorm Cell Therapeutics Inc. on August 14, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRAINSTORM CELL THERAPEUTICS INC. Date: August 14, 2024 By: /s/ Chaim Lebovits Chaim Lebovits President and Co-Chief Executive Officer